Compugen Ltd. and Onconetix Compared on Valuation and Earnings
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A comparison of Compugen Ltd. and Onconetix found that Compugen Ltd. has higher revenue and earnings than Onconetix. Onconetix, however, is currently trading at a lower price-to-earnings ratio than Compugen Ltd.
From tickerreport.com
Why it matters
Equities research analysts believe Compugen Ltd. is more favorable than Onconetix due to its stronger consensus rating and higher possible upside. Compugen Ltd. has 12.2% of its shares held by institutional investors, while Onconetix has 23.9%.
From tickerreport.com
Who's involved
- Compugen Ltd.Publicly traded Israeli drug discovery company subject to valuation analysis
- Gilead SciencesCompany that received a license for the drug candidate GS-0321 from Compugen Ltd.
Keep exploring
The entities involved
-
Compugen Ltd.
publicly traded Israeli drug discovery company
Nothing else this week.
-
Europe
terrestrial continent located in north-western Eurasia